|
factor
|
---|
(A) Outcome
|
dependent independent
|
Odds ratio
|
95%CI
|
P
|
---|
1) HTLV-1 mono-infection
|
TT vs TG/GG
|
1.11
|
0.62-1.99
|
0.72
|
2) Co-infection
|
TT vs TG/GG
|
0.54
|
0.04-6.88
|
1.00
|
3) High mRNA Expression*
|
TT vs TG/GG
|
6.25
|
1.16-33.75
|
0.04
|
4) ATL
(B)
|
TT vs TG/GG
|
1.50
|
0.60-3.75
|
0.39
|
5) Low mRNA Expression
|
HTLV-1 mono vs DN
|
0.34
|
0.06-2.04
|
0.24
|
6) Low mRNA Expression
|
HCV mono vs DN
|
0.29
|
0.07-2.23
|
0.15
|
7)) Low mRNA Expression
|
Co-Inf** vs HTLV-1-mono**
|
9.5
|
2.06-43.76
|
0.004
|
8) ATL
|
low expression or not
|
0.8
|
0.14-4.74
|
0.81
|
- (A) Upper 4 lines; assessing the risk of 1) HTLV-1 persistent infection, 2) super-imposed HTLV-1 infection with HCV (co-infection), 3) high IL-28B mRNA expression, and 4) ATL development when the genotype is a risk factor (B) Lower 4 lines; assessing the risk factors described in the outcome, the IL-28B mRNA expression level in peripheral blood (5, 6, and 7), and ATL development (8). Consequently, similarly to HCV, HTLV-1 is associated with up-regulation of IL-28B mRNA along with the TT homozygote, and co-infection with HTLV-1 and HCV paradoxically down-regulates the mRNA level
- *; IL-28B Expression level, Co-inf = co-infection with HTLV-1 and HCV, mono = mono-infection